Earendil Labs pricing

No price, rate card or unit of charge exists, because the platform is not sold on its own. The public figures come from deal announcements: $125 million upfront from Sanofi in April 2025 for HXN-1002 and HXN-1003 against a total of up to $1.8 billion in milestones and royalties, a broader discovery collaboration in January 2026 worth up to $2.56 billion, and $787 million raised from investors including Sanofi, Dimension Capital, DST Global Partners and a Hillhouse and Pfizer biotech fund. Those are contract ceilings and investment totals rather than money received or a price a buyer could pay.

Earendil Labs full profile Earendil Labs alternatives

Pricing terms

How Earendil Labs pricing works

Pricing model: Negotiated collaboration and licensing. Earendil earns through upfront payments, development and commercial milestones and royalties on individual programs licensed to pharmaceutical partners, rather than by selling platform access. No software license or subscription is offered.
Implementation: Not applicable and not published. Nothing is installed or configured for a buyer; the company carries its own discovery and preclinical costs and licenses finished programs. Partners take development and commercialization from there.

Compared on price

Earendil Labs pricing against its alternatives

Published prices for Earendil Labs and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.

All Earendil Labs alternatives →

E
Earendil LabsNo published price
B
BioMapNo published price
L
LabGeniusNo published price
A
AbsciNo published price
A
A-Alpha BioNo published price
E
Eikon TherapeuticsNot applicable
B
Biolojic DesignNo published price
G
GaluxNo published price
X
XtalPiNo published price

Questions

Earendil Labs pricing, answered

How much does Earendil Labs cost?

Earendil Labs does not publish a price. The public figures come from deal announcements: $125 million upfront from Sanofi in April 2025 for HXN-1002 and HXN-1003 against a total of up to $1.8 billion in milestones and royalties, a broader discovery collaboration in January 2026 worth up to $2.56 billion, and $787 million raised from investors including Sanofi, Dimension Capital, DST Global Partners and a Hillhouse and Pfizer biotech fund.

Does Earendil Labs charge an implementation fee?

Not applicable and not published. Nothing is installed or configured for a buyer; the company carries its own discovery and preclinical costs and licenses finished programs. Partners take development and commercialization from there.